Cristália signs licensing deal for Formosa’s APP13007
Pharmaceutical Technology
JANUARY 29, 2024
Cristália has signed an agreement to license exclusive rights to market Formosa Pharmaceuticals’ APP13007 in Brazil.
Pharmaceutical Technology
JANUARY 29, 2024
Cristália has signed an agreement to license exclusive rights to market Formosa Pharmaceuticals’ APP13007 in Brazil.
Pharmaceutical Technology
MARCH 27, 2024
The market for multiple sclerosis therapies is expected to be worth over $41bn by 2030, according to GlobalData.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 8, 2022
According to the revised deal, Daiichi Sankyo and Kite will transfer the Marketing Authorization for Yescarta to Gilead’s Japan subsidiary, Gilead Sciences K.K., The therapy’s sales and promotion works in Japan following the transfer of marketing authorisation will be carried out by the Kite Cell Therapy Business Unit at Gilead Sciences K.K.
Pharmaceutical Technology
JANUARY 2, 2023
South Korean biotechnology company Alteogen has signed an exclusive license agreement with Swiss company Sandoz to develop and market biosimilar products that are enabled by the former’s Hybrozyme technology. Additionally, the company will have an option to license Alteogen’s Hybrozyme technology for two more products.
Pharmaceutical Technology
DECEMBER 5, 2022
Women’s healthcare company TherapeuticsMD has sign ed agreements for licensing its products to the Mayne Pharma affiliate in the US. Additionally, TherapeuticsMD will grant Mayne the exclusive license to market Annovera in the US. TherapeuticsMD will also get a 20-year royalty stream linked to Mayne’s net product sales.
Pharmaceutical Technology
OCTOBER 30, 2023
Helinus will receive €42m upfront and will be in line to receive up to €143m in regulatory and sales-based milestone payments.
Drug Discovery World
MAY 31, 2024
Jaguar Health’s out-licensing agreement with Magdalena Biosciences to develop novel, natural prescription medicines derived from plants for mental health indications, has been expanded. ” The US schizophrenia market is projected to grow to $8.06 billion by 2030, according to a market research report by Market Research Future.
Let's personalize your content